217 related articles for article (PubMed ID: 29989452)
1. Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice.
Passiglia F; Commendatore O; Vitali M; Conca R
Future Oncol; 2018 Jun; 14(13s):41-60. PubMed ID: 29989452
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance.
Pu X; Wu L; Su D; Mao W; Fang B
BMC Cancer; 2018 Nov; 18(1):1082. PubMed ID: 30409126
[TBL] [Abstract][Full Text] [Related]
3. Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy.
Li X; Eastham J; Giltnane JM; Zou W; Zijlstra A; Tabatsky E; Banchereau R; Chang CW; Nabet BY; Patil NS; Molinero L; Chui S; Harryman M; Lau S; Rangell L; Waumans Y; Kockx M; Orlova D; Koeppen H
J Pathol; 2024 Jun; 263(2):190-202. PubMed ID: 38525811
[TBL] [Abstract][Full Text] [Related]
4. [Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer].
Huang C; Yang X
Zhongguo Fei Ai Za Zhi; 2021 Nov; 24(11):777-783. PubMed ID: 34802209
[TBL] [Abstract][Full Text] [Related]
5. Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1/PD-L1 blockade in the clinical spectrum of lung cancer.
Li Y; Sharma A; Schmidt-Wolf IGH
Mol Cancer; 2024 Apr; 23(1):80. PubMed ID: 38659003
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy in the treatment of non-small cell lung cancer.
Sundar R; Soong R; Cho BC; Brahmer JR; Soo RA
Lung Cancer; 2014 Aug; 85(2):101-9. PubMed ID: 24880938
[TBL] [Abstract][Full Text] [Related]
7. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.
Morgensztern D; Campo MJ; Dahlberg SE; Doebele RC; Garon E; Gerber DE; Goldberg SB; Hammerman PS; Heist RS; Hensing T; Horn L; Ramalingam SS; Rudin CM; Salgia R; Sequist LV; Shaw AT; Simon GR; Somaiah N; Spigel DR; Wrangle J; Johnson D; Herbst RS; Bunn P; Govindan R
J Thorac Oncol; 2015 Jan; 10(1 Suppl 1):S1-63. PubMed ID: 25535693
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges.
Xiang Y; Liu X; Wang Y; Zheng D; Meng Q; Jiang L; Yang S; Zhang S; Zhang X; Liu Y; Wang B
Front Immunol; 2024; 15():1366260. PubMed ID: 38655260
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy and Immunotherapy Combinations in Non-small Cell Lung Cancer: A Promising Future?
Hanna GG; Illidge T
Clin Oncol (R Coll Radiol); 2016 Nov; 28(11):726-731. PubMed ID: 27519157
[TBL] [Abstract][Full Text] [Related]
10. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution.
McGranahan N; Rosenthal R; Hiley CT; Rowan AJ; Watkins TBK; Wilson GA; Birkbak NJ; Veeriah S; Van Loo P; Herrero J; Swanton C;
Cell; 2017 Nov; 171(6):1259-1271.e11. PubMed ID: 29107330
[TBL] [Abstract][Full Text] [Related]
11. The non-small cell lung cancer immune landscape: emerging complexity, prognostic relevance and prospective significance in the context of immunotherapy.
Anichini A; Tassi E; Grazia G; Mortarini R
Cancer Immunol Immunother; 2018 Jun; 67(6):1011-1022. PubMed ID: 29516154
[TBL] [Abstract][Full Text] [Related]
12. Editorial: Analysis of tumor immune microenvironments and molecular mechanism to reveal the dilemma of immunotherapy for advanced non-small cell lung cancer.
Roviello G; Vascotto IA; Catalano M
Front Immunol; 2024; 15():1415608. PubMed ID: 38726009
[No Abstract] [Full Text] [Related]
13. Immuno-targeted combinations in oncogene-addicted non-small cell lung cancer.
Listì A; Barraco N; Bono M; Insalaco L; Castellana L; Cutaia S; Ricciardi MR; Gristina V; Bronte E; Pantuso G; Passiglia F
Transl Cancer Res; 2019 Jan; 8(Suppl 1):S55-S63. PubMed ID: 35117064
[TBL] [Abstract][Full Text] [Related]
14. Beyond binary: bridging neutrophil diversity to new therapeutic approaches in NSCLC.
Horvath L; Puschmann C; Scheiber A; Martowicz A; Sturm G; Trajanoski Z; Wolf D; Pircher A; Salcher S
Trends Cancer; 2024 May; 10(5):457-474. PubMed ID: 38360439
[TBL] [Abstract][Full Text] [Related]
15. Antibodies against endogenous retroviruses promote lung cancer immunotherapy.
Ng KW; Boumelha J; Enfield KSS; Almagro J; Cha H; Pich O; Karasaki T; Moore DA; Salgado R; Sivakumar M; Young G; Molina-Arcas M; de Carné Trécesson S; Anastasiou P; Fendler A; Au L; Shepherd STC; Martínez-Ruiz C; Puttick C; Black JRM; Watkins TBK; Kim H; Shim S; Faulkner N; Attig J; Veeriah S; Magno N; Ward S; Frankell AM; Al Bakir M; Lim EL; Hill MS; Wilson GA; Cook DE; Birkbak NJ; Behrens A; Yousaf N; Popat S; Hackshaw A; ; ; Hiley CT; Litchfield K; McGranahan N; Jamal-Hanjani M; Larkin J; Lee SH; Turajlic S; Swanton C; Downward J; Kassiotis G
Nature; 2023 Apr; 616(7957):563-573. PubMed ID: 37046094
[TBL] [Abstract][Full Text] [Related]
16. Exploiting Tertiary Lymphoid Structures to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy.
Petroni G; Pillozzi S; Antonuzzo L
Cancer Res; 2024 Apr; 84(8):1199-1209. PubMed ID: 38381540
[TBL] [Abstract][Full Text] [Related]
17. Beyond chemotherapy: Emerging biomarkers and therapies as small cell lung cancer enters the immune checkpoint era.
Della Corte CM; Gay CM; Byers LA
Cancer; 2019 Feb; 125(4):496-498. PubMed ID: 30620399
[TBL] [Abstract][Full Text] [Related]
18. Cryoablation and immunity in non-small cell lung cancer: a new era of cryo-immunotherapy.
Velez A; DeMaio A; Sterman D
Front Immunol; 2023; 14():1203539. PubMed ID: 37671163
[TBL] [Abstract][Full Text] [Related]
19. [Advanced non-small cell lung cancer - pioneer in personalized oncology].
Saalfeld FC; Aust DE; Wermke M
Dtsch Med Wochenschr; 2023 Sep; 148(18):1166-1173. PubMed ID: 37657454
[TBL] [Abstract][Full Text] [Related]
20. Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention.
Jadus MR; Natividad J; Mai A; Ouyang Y; Lambrecht N; Szabo S; Ge L; Hoa N; Dacosta-Iyer MG
Clin Dev Immunol; 2012; 2012():160724. PubMed ID: 22899945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
